Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (AJMC®). She joined AJMC® in 2013 and is the primary staff editor for Evidence-Based Oncology, the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for AJMC®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for AJMC readers.
Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on LinkedIn.
Results presented at the American Society of Clinical Oncology Annual Meeting showed a 21.4-month advantage for autologous stem cell transplant (ASCT) over a common triplet therapy in progression-free survival (PFS) but no advantage in overall survival (OS).
Practice-changing data from the DESTINY-Breast04 study, presented during the 2022 Annual Meeting of the American Society of Clinical Oncology in Chicago, show that trastuzumab deruxtecan reduced the risk of disease progression or death by 50% compared with chemotherapy for human epidermal growth factor receptor-2 (HER2)–low patients with both hormone receptor (HR)–positive and HR-negative disease.
Thanos Zomas, MD, global medical lead, Lymphoma and Leukemia, and global medical lead, Adcetris Program, at Takeda Oncology discusses updated results from the ECHELON-1 study.
David R. Penberthy, MD, MBA, is medical director, Radiation Oncology, Bon Secours-Southside Medical Center in Petersburg, Virginia, and president of the Association of Community Cancer Centers for the 2022-2023 term.
TROPiCS-02, a phase 3 study, was presented during a session on breast cancer at the 2022 Annual Meeting of the American Society of Clinical Oncology.
Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care Associates, current president of the Community Oncology Alliance, and associate editor of Evidence-Based Oncology™, discusses his partnership with Sema4 and LabCorp and their joint goal to advance whole-exome sequencing (WES) for targeted oncology treatment.
Enrique Ocio, MD, PhD, hematology department head, Marqués de Valdecilla University Hospital, Santander, Spain, discusses phase 1b trial results for subcutaneous (sub-Q) vs intravenous isatuximab, both formulations administered in combination with pomalidomide and dexamethasone for relapsed/refractory multiple myeloma (RRMM).
The collaboration, put in place through a Memorandum of Understanding, was presented Saturday in a keynote address by WHO Cancer Control Officer André Ilbawi, MD, during the presidential symposium at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago.
Data presented at ASCO show that after 6 years, patients with advanced Hodgkin lymphoma who were treated with a combination of brentuximab vedotin and chemotherapy had a sharply reduced risk of death and a reduced risk of a secondary cancer.
Findings from the phase 3 SHINE trial could make ibrutinib the standard treatment option for older patients with mantle cell lymphoma (MCL), who often cannot tolerate chemotherapy or transplant strategies, according to study authors.
For the second year, the meeting will focus on health equity, as American Society of Clinical Oncology (ASCO) President Everett Vokes, MD, FASCO, has selected the theme “Advancing Equitable Cancer Care Through Innovation.”
Randall A. Oyer, MD, medical director, oncology, and medical director, Cancer Risk Evaluation Program, Lancaster General Health, and clinical professor of cancer biology at Penn Medicine, discusses the recent American Society of Clinical Oncology/Association of Community Cancer Centers recommendations for improving diversity in clinical trials.
Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care Associates, current president of the Community Oncology Alliance, and associate editor of Evidence-Based Oncology™, talks with us ahead of the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
The approvals were announced by Bristol Myers Squibb (BMS), maker of the 2 immunotherapy treatments approved for 1 combination: nivolumab (Opdivo), the first approved PD-1 immune checkpoint inhibitor, and ipilimumab (Yervoy), which activates the immune system by targeting CTLA-4.
Data to be presented next week during the American Society of Clinical Oncology Annual Meeting show that for every 10% increase in public welfare spending, there was a 4.55% narrowing of the 5-year overall survival (OS) disparity between Black and White patients with cancer.
Miruna Sasu, PhD, MBA, president and CEO of COTA Healthcare, discusses 3 ways in which the FDA can provide, and has provided, assistance on the capture of real-word data (RWD) in electronic medical records.
Authors wrote that their analysis was the first to combine incidence and mortality of overall BTC, and its anatomic subtypes, into a single study
Miruna Sasu, PhD, MBA, president and CEO of COTA Healthcare, discusses the medicines discovery process and how real-world data can be used to evaluate patient and tumor response to treatment regimens.
Miruna Sasu, PhD, MBA, president and CEO of COTA Healthcare, delves into how real-world data and evidence generation have changed, both within the past year and since the beginning of the COVID-19 pandemic.
Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, discusses how community oncology practices have heightened their outreach efforts to entice patients back in for cancer screenings and the importance of thinking outside the box to overcome staffing shortages in the oncology space.
Cholangiocarcinoma (CCA), or bile duct cancer, is classified by its location, with intrahepatic CCA (iCCA) referring to those cancers that form in bile ducts within the liver.
Officials from Novartis emphasized that the ribociclib-fulvestrant combination is the only one in the CDK4/6 inhibitor class to demonstrate an overall survival benefit when used in a first-line setting among postmenopausal women.
Patients with type 2 diabetes who used the Omnipod 5 had lower A1C after 8 weeks. Those who had been using multiple daily injections achieved the greatest benefits in reduced hypoglycemia and reduced insulin use.
The project seeks to develop materials explaining chemotherapy regimens for patients with biliary tract cancers and then translate these materials into “standardized, high-quality, free, and easily accessible resources."
Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, addresses how the pandemic may have influenced cancer screening and diagnosis rates.
Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope in Duarte, California, spoke March 4 at the closing session of the Association for Community Cancer Centers (ACCC) Annual Meeting & Cancer Business Summit in Washington, DC.
Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, addresses considerations for getting a second COVID-19 booster, or a fourth dose, among survivors of breast cancer or patients currently undergoing treatment as well as those who may be immunocompromised.
The study used rats with monocrotaline (MCT)-induced PAH to examine whether adding dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, would offer any add-on benefit when used with sildenafil.
Coverage from the Community Oncology Alliance 2022 Community Oncology Conference, held March 17-18 in Kissimmee, Florida.
Coverage from the Association of Community Cancer Centers 2022 Annual Meeting and Cancer Center Business Summit, held in Washington, DC, March 2-4.
259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831
© 2025 MJH Life Sciences®
All rights reserved.
